In addition, the dabrafenib/trametinib combination therapy is also approved for locally advanced/metastatic anaplastic thyroid cancer and advanced NSCLC harboring a BRAF V600 mutation. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.